Cipla
Sudhir Soni is a seasoned professional in the pharmaceutical and life sciences industry, currently serving as the Director and Head of QA IT, CSV, and GxP Compliances at Cipla since June 2021. Sudhir previously held the position of Associate Director in the same department at Cipla. Prior to this, Sudhir worked at Sun Pharmaceuticals Ltd. as a Global Quality Auditor and DGM in Corporate Quality Audit & QAIT Project Management from December 2015 to June 2021. Additional experience includes a role as Domain Consultant at Wipro Ltd., Senior Manager of Quality Assurance at Reliance Life Sciences, Executive QA at Torrent Pharmaceuticals, and Quality Assurance Officer at Aristo Pharma. Sudhir possesses extensive expertise in GMP & GxP Audits, Data Integrity, and IT Compliance regulations. Sudhir's academic background includes a degree from Barkatullah Vishwavidyalaya.
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.